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Abstract: The cancer metabolic reprogramming allows the maintenance of tumor proliferation,
expansion and survival by altering key bioenergetics, biosynthetic and redox functions to meet the
higher demands of tumor cells. In addition, several metabolites are also needed to perform signaling
functions that further promote tumor growth and progression. These metabolic alterations have been
exploited in different cancers, including acute myeloid leukemia, as novel therapeutic strategies both
in preclinical models and clinical trials. Here, we review the complexity of acute myeloid leukemia
(AML) metabolism and discuss how therapies targeting different aspects of cellular metabolism have
demonstrated efficacy and how they provide a therapeutic window that should be explored to target
the metabolic requirements of AML cells.
Keywords: metabolism; acute myeloid leukemia; preclinical and clinical trials on metabolic targets
1. Introduction
Acute myeloid leukemia (AML) is the most frequent acute leukemia in adults, with a median age
at diagnosis of around 68 years. It is an aggressive disease, requiring an urgent accurate diagnosis and a
multifaceted, timely, and effective therapeutic approach in order to achieve disease remission and even
long-term cure [1]. Despite the progress in prognostic markers, the optimization of cytotoxic therapy
and advances in supportive care, the long-term outcome of AML is not encouraging, particularly in
elderly patients [2]. The intrinsic refractoriness of the disease in the eldest population in association
with existing comorbidities contribute towards a high toxicity profile upon application of the standard
cytotoxic therapy, yielding an overall survival (OS) lower than 1 year [3]. In fact, the genetic landscape
of patients older than 60 years is different from the young ones, namely presenting adverse cytogenetic
profile, overexpression of drug resistance genes, and a high frequency of mutations in genes involved
in epigenetic regulation [4,5]. Noteworthy, mutations on these epigenetics-related genes are also
documented in healthy elderly population in an age dependent manner, increasing the risk of
hematologic neoplasms [6]. Thus, it is important for the old/refractory or unfit patients to look for
more effective and less toxic therapies and, in such context, metabolic reprogramming occurring in
leukemic cells presents as a promising target [7].
The strategies used by malignant cells to escape the mechanisms of homeostasis control are
appreciably varied, with metabolic reprogramming playing a key role in the final outcome. Metabolic
reprogramming is considered a hallmark of cancer and, basically, consists of providing a rewired
metabolism to support high metabolic demands for the elevated rate of growth and proliferation.
Indeed, to maintain tumor proliferation, expansion, and survival, a reprogramming of metabolism
must be performed to satisfy key bioenergetics, biosynthetic and redox functions of malignant cells.
In addition to the altered metabolism, several metabolites have a signaling function, promoting tumor
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growth and progression [8]. Numerous studies and clinical trials demonstrate both the importance of
metabolic adaptation for the survival of AML cells and the therapeutic potential of attacking different
metabolic pathways. In the last years, several drugs have been developed to target specific metabolic
pathways and enzymes, metabolites, and signaling pathways. Several studies show an acceptable
toxicity of some of these metabolism-affecting drugs even when used in combination with standard
chemotherapy. In this review, we intend to highlight the most recent data in the field and, whenever
possible, discuss the clinical impact.
2. Metabolic Reprogramming in Acute Myeloid Leukemia
Nutrient addiction is considered a hallmark of cancer and this metabolic reprogramming has
two fundamental aspects: first, the rapid production of ATP and intermediates for the synthesis of
nucleotides, amino acids, lipids, and redox elements (NADPH); second, the reset of the nutrient-sensing
signaling pathways operating in physiological conditions. In addition, to support fast cell division,
the tumor cells must generate enough energy and escape from cell cycle checkpoints control. The
Warburg effect is a well characterized metabolic phenotype of tumor cells, which consists of increased
glycolytic flux for the rapid ATP generation per unit time, instead of producing ATP through oxidative
phosphorylation (OXPHOS) [9] (Figure 1). Below, a summary of the main metabolic reprogramming
findings on AML is presented.
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2.1. Glycolysis and Energetic Metabolism
Enhanced glycolysis has been observed in AML cell lines and in human primary AML blasts [10],
while both the phosphoinositide 3-kinase (PI3K)/serine-threonine protein kinase B (AKT) and the
mammalian target of rapamycin (mTOR) seemingly contribute to this glycolytic metabolism [11,12].
It has also been reported that AML patients have a distinct glucose metabolic signature as well as six
serum metabolites involved in the glycolytic pathway which were identified and proposed as new
prognostic biomarkers in the subgroup of patients with normal cytogenetics [13].
The high glycolytic profile has been shown to be important for chemotherapy response, having been
found to confer greater resistance to apoptosis induced by All-Trans-Retinoic-Acid (ATRA) and arsenic
trioxide in primary blasts and AML cell lines, besides having an impact on the clinical prognosis [14].
Increased glycolysis also contributes to the resistance of AML patients to cytarabine [15,16]. The impact
on clinical outcome is also reported—AML patients who did not achieve remission when compared to,
either, healthy controls, or remission patients, show increased levels in distinct glycolysis elements, such
as HIF1a, hexokinase 2 (HK2), glucose transporter 1 (GLUT1), and lactate dehydrogenase (LDH) [15].
Thus, the magnitude of myeloblast glycolysis has been proposed as an effective method to determine
the pre-treatment prognosis of AML [10]. Additionally, leukemic stem-cells (LSCs) might have a
role in inducing insulin resistance and decreasing insulin secretion, in order to increase the supply
of glucose to malignant cells, therefore inducing alterations of systemic physiology by co-opting
systemic regulatory mechanisms in their favor [17]. Metabolic plasticity allows AML cells to balance
between glycolysis and OXPHOS, however, these metabolic adaptations likely differ between AML
sub-types [12] and also within leukemic cells from the same patient [18].
2.2. Amino Acid Metabolism
Metabolic reprogramming in cancer cells occurs far beyond the Warburg Effect [19,20]. The high
glycolytic rate with concomitant ATP production requires the availability of precursors for anabolic
pathways, such as intermediates of the tricarboxylic acid (TCA) cycle and the pentose phosphate
pathway (PPP) (Figure 1). Biosynthetic pathways are also required for the production of nutrients
and metabolization of the three major classes of macromolecules (proteins, lipids, nucleic acids),
essential for cell growth and proliferation. Commonly, other carbon sources such as amino acids,
particularly glutamine, allow malignant cells to rely on high glycolytic rates. Glutaminolysis is an
important mitochondrial metabolic pathway catalyzed by glutaminase (GLS) (Figure 1). Glutamine
enters cells through specific transporters, is catabolized into ammonia and glutamate, which in turn
could be deaminated and have its carbon skeleton converted to alfa-ketoglutarate (alpha-KG) to
support anaplerosis of the TCA cycle. Alpha-KG can proceed backwards through the TCA cycle, by
reductive carboxylation operated by the enzyme isocitrate dehydrogenase (IDH) producing citrate
and further supporting synthesis of acetyl-CoA and lipids (Figure 1). The alpha-KG also works on
glutamine metabolism and can be oxidatively metabolized via TCA to lactate. Apparently, this process
might support lipogenesis in tumor cells [21].
Glutaminolysis supplies nitrogen for protein and nucleotide synthesis and is necessary to maintain
the redox state through the production of NADPH (Figure 1). It is reported that glutamine reactivates
the mammalian target of rapamycin complex 1 (mTORC1), specifically through its conversion to
glutamate and restoration of non-essential amino acid pool [22]. It is also documented that glutamine
levels control OXPHOS in AML cells and glutaminolysis inhibitors activate mitochondrial apoptosis,
whereas in normal CD34+ hematopoietic progenitors, glutaminase isoform 1 (GLS1) inhibition does not
result in reduced proliferation and/or survival of these cells [23,24]. Therefore, inhibiting the glutamine
metabolism in AML has been an appealing strategy against this malignancy [25,26]. Nevertheless, the
role of glutamine in cancer metabolism is far more complex. Other amino acids such as asparagine
have been shown to cooperate with glutamine in favoring malignant cell metabolism. In cells deprived
of glutamine, asparagine can rescue the growth and survival of cells, as it maintains protein synthesis
(Figure 1) [27]. Accordingly, the introduction of asparaginase blocks the ability of cells to adhere to
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glutamine deprivation [27]. Human LSCs have been consistently described as selectively dependent
upon amino acid metabolism (e.g., glutamine, glutamate, and proline) for OXPHOS and survival in
de novo AML patients, while not depending on amino acid metabolism when isolated from relapsed
patients [28,29]. LSCs from relapsed patients can, apparently, metabolically compensate by increasing
fatty acid metabolism [29].
2.3. Fatty Acid Metabolism
Lipid metabolism dysregulation has been established as an important metabolic phenotype in
malignant cells. It is overly reported that the various processes inherent to lipid metabolism, such
as fatty acid synthesis and fatty acid oxidation (FAO) are altered in many cancers [30,31]. In AML
a reprogramming of lipid metabolism has also been shown, both in the leukemic hematopoietic
precursors and the signaling that these cells induce on the bone marrow microenvironment, namely
on bone marrow adipocytes [32]. Bone marrow adipocytes interact with primary myeloid leukemia
cells from patients promoting their survival and proliferation [33]. In this adipocyte-leukemic cell
interaction, blasts alter metabolism of adipocytes by activating lipolysis thus allowing the transfer of
fatty acids from adipocytes to blasts. Curiously, a reservoir of LSCs was found in gonadal adipose
tissue, further documenting the dependence of hematopoietic stem-cells (HSCs) and LSCs on lipid
metabolism [34].
FAO, which takes place in the mitochondrial matrix, is a process used by leukemic cells to promote
their survival and quiescence [35]. The exploration of this metabolic pathway by the malignant cells
allows for both the generation of citrate in the TCA cycle and of antioxidant defenses and reduced
coenzymes, FADH2 and NADH, which are then oxidized to generate ATP via OXPHOS (Figure 1).
Carnitine palmitoyl transferase 1A (CPT1A) and carnitine transporter CT2 (SLC22A16), rate limiting
actors of FAO, are overexpressed in AML and constitute novels targets for a subset of AML [36,37] (for
a review, see [18]).
The optimization of lipid metabolism is essential for cell proliferation and synthesis of membrane
lipid components under stress situations [35]. Of seemingly particular relevance in the global context
of metabolism reprogramming is the finding that lipid anabolism is strongly altered in IDH1 mutant
AML cells with a crucial dysregulation of fatty acid metabolism and fluxes [32].
2.4. Metabolic Enzymes and Epigenetic Modifiers
In the last decade, mutations in two key metabolic enzymes, cytosolic and mitochondrial isocitrate
dehydrogenases (IDH1 and IDH2, respectively), have been identified in myeloid malignancies [38,39].
IDHs catalyze the oxidative decarboxylation of isocitrate producing alpha-KG, NADPH/NADH, and
carbon dioxide (Figure 1). These reactions provide the NADPH needed for lipid biogenesis and
protection to oxidative damage, facilitating the function of alpha-KG-dependent dioxygenases. Genes
encoding isoforms of IDH1 and IDH2 are mutated in approximately 15–20% of AML patients [40,41].
These mutations are acquired early in the leukemogenic process and are kept stable throughout
the disease’s evolution, the leukemic IDH mutated clone being able to survive the initial treatment,
thus contributing to relapse [42]. IDH mutations induce a neomorphic activity (resulting from
a rearrangement of the enzyme’s active site), leading to the production of the oncometabolite
2-hydroxyglutarate (2-HG) (Figure 1), which is a competitive inhibitor of multiple alpha-KG-dependent
dioxygenases, including histone demethylases and the TET family of 5-methlycytosine hydroxylases
(e.g., TET2). 2-HG promotes DNA and histone hypermethylation, altering the epigenetic landscape
of cells. This phenomenon blocks cellular differentiation and promotes cellular transformation and,
thus, tumor initiation and progression [38,43]. IDH mutations are both mutually exclusive with each
other and with mutations in TET2. In most studies, IDH mutations were found to be heterozygous,
resulting in a gain of function phenotype, occurring primarily in three arginine residues critical
for isocitrate binding-the R132 codon in IDH1 and the R140 and R172 in IDH2 [44,45]. It has been
proposed that the mutant allele burden of IDH can be a biomarker of response to treatment in AML
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patients [46]. Nonetheless, there is still some controversy about the prognostic value of IDH mutations
in AML. A systematic review and a meta-analysis concluded that IDH1 mutations confer worse OS
and event-free survival (EFS), especially in patients with normal cytogenetics, and that IDH2 mutation
improves OS particularly in patients with intermediate-risk AML [47].
2.5. Signaling Pathways and Autophagy
As mentioned above, multiple signaling pathways control metabolic reprogramming of leukemic
cells including PI3K/AKT, mTOR, and the AMP-activated protein kinase (AMPK). This is a complex
network hub of signaling proteins and kinases functioning as sensors and regulators of response
to environmental stimuli which govern cell growth, proliferation, and survival. These pathways
integrate the availability of nutrients, mitogenic growth factors, cellular energy levels, and stress with
the biosynthesis of three major classes of macromolecules (proteins, lipids, and nucleic acids). These
signaling pathways have been reported to regulate normal hematopoiesis, reviewed in [48], but are
frequently overexpressed in AML [49]. While aberrant PI3K/AKT pathway activation is found in
50%–80% of AML cases [50], mTORC1 appears to be active in all reported AML cases [51,52].
mTORC1 is an important anabolic kinase in the regulation of normal hematopoiesis which is
inhibited when amino acids and oxygen levels are decreased. Insofar, mTORC1 suppression contributes
to HSCs maintenance by repressing mitochondrial biogenesis. Being HSCs in the hypoxic environment
of the bone marrow, they are dependent on glycolysis for their energy needs more than of OXPHOS, so
mTORC1 suppression is vital for their homeostasis [53,54]. mTORC1 is negatively regulated by AMPK,
a key sensor of the cellular energy status, which suppresses anabolic processes and promotes multiple
catabolic processes critical in maintaining metabolic homeostasis and survival. In HSCs, AMPK was
demonstrated to be fundamental for the maintenance of energy homeostasis [55]. Our results also
showed that AMPK is activated in some AML cell lines, which can be related to their metabolic
profile [56], suggesting that the use of metabolic inhibitors which activate AMPK in combination with
chemotherapy should be explored in the treatment of AML.
Constitutive activation of mTORC1 has been systematically identified in patients’ myeloid blast
cells. There are several mechanisms responsible for this activation, namely, activating mutations in the
receptor tyrosine kinase FLT3, mutations in the c-KIT gene, increased production of angiogenic factors
(vascular endothelial growth factor (VEGF) and angiopoietins) and increased expression of IGF-1
growth factor [57]. Furthermore, activating signals from the microenvironment, including chemokines
and adhesion molecules, are also factors that contribute to this signaling pathway activation [58].
mTORC1 is found to be activated even in the absence of an elevated PI3K/AKT signaling [12,59].
In spite of this evidence, the role of AMPK, mTORC1 and/or PI3K/AKT in AML cells is still controversial,
having both tumor-suppressor and -promoter functions been assigned to these actors [48,52,56,60–65].
Importantly, this signaling network plays a key role in controlling the balance between the promotion
of anabolism and the suppression of catabolic pathways such as macroautophagy (hereafter named
autophagy). Autophagy is a tightly-regulated catabolic response to numerous cellular stresses such as
nutrient starvation, hypoxia, growth factor deprivation, metabolic stress, and most notably, cancer
therapy drugs.
Curiously, similar to the signaling pathways controlling this catabolic degradative process,
dysregulation of autophagy has been extensively described in AML with both tumor-suppressor and
-promoter functions [56,66–68]. Autophagy is often found reduced in human AML blasts and the
loss of key autophagy genes leads to leukemia initiation and progression in mouse models [69–71].
Importantly, different sequencing and in silico studies showed a high frequency of AML patients
carrying heterozygous deletions, missense mutations, or copy number variations of autophagy
genes, particularly AML patients with complex karyotypes [69,72,73]. These studies are further
supported by the correlation between the heterozygous chromosomal loss of 5q, 16q, or 17p and
the encoded regions for the autophagy genes ATG10 and ATG12, GABARAPL2 and MAP1LC3B, or
GABARAP, respectively [69]. Accordingly, the heterozygous loss of ATG5 increases the progression
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and aggressiveness of an AML model [69]. A recent study challenges these observations and suggests
a tumor-promoting role for autophagy, by showing that knockdown of ATG5 in primary AML cells
resulted in impaired engraftment of human cells in immunodeficient NSG mice [74].
We have previously addressed the relationship between signaling pathways and autophagy in
the context of AML cell lines [12]. The results showed that preferential OXPHOS metabolism of AML
cells is associated with constitutive co-activation of AMPK and mTORC1 and increased autophagy,
while a glycolytic profile is mainly associated with AKT/mTORC1 activation and low autophagy
flux, highlighting the relevance of signaling pathways and autophagy on metabolic reprograming of
AML [12].
3. Modulation of AML Metabolism
New drugs targeting metabolism in AML have been developed and studied in preclinical and
clinical trials. These drugs target, among other, glycolysis, amino acids and fatty acid metabolism,
signaling pathways, autophagy, metabolic enzymes (e.g., IDH), and epigenetic modifiers. Importantly,
a clinical trial, still in the recruitment phase, aims to determine the global metabolic adaptations that
occur following exposure to standard chemotherapeutic agents using peripheral blood mononuclear
cells from AML patients (NCT02581917). Below, a brief summary of the main approaches targeting
metabolism in AML is presented (data from https://clinicaltrials.gov).
3.1. Targeting Glycolysis and Energetic Metabolism
An effective anti-leukemia strategy is to counteract the up-regulated glycolysis, following the
example of its proven application in several neoplasms. Glycolysis can be blocked by substrate
restriction and/or by the inhibition of glycolytic enzymes. Reducing glucose uptake by attacking one
of the two main transporters, such as GLUT1, is a strategy that has also been explored in hematological
malignancies, such as acute lymphoid leukemia and multiple myeloma [75,76]. In AML, there is also
evidence that high levels of GLUT1 are associated with poor response to chemotherapy and inhibiting
glycolysis is a potential anti-tumor strategy [16]. Inhibition of glycolysis with glycolytic inhibitor
2-deoxyglucose (2-DG), which cannot be metabolized by glycolytic enzymes, has been documented
to potentiate the cytotoxicity of the chemotherapeutic drug cytarabine [13]. It was also found that
2-DG has anti-leukemic activity in AML cell lines with FLT3 and c-KIT mutations, but this warrants
validation in a clinical setting [77]. Another potent inhibitor of glycolysis is 3-bromopyruvate (3-BrPA),
which directly inhibits HK2 and triggers apoptosis in a variety of cancers, including the AML cell line
HL-60 [16]. It is also reported that AML cell lines resistant to sorafenib (a kinase inhibitor used for
FLT3-ITD positive AML) are sensitive to both 2-DG and 3-BrPA [78]. Nevertheless, inhibiting glycolysis
requires further investigation to define the clinical applicability of this strategy. Regarding oxidative
metabolism, there is an ongoing phase I clinical trial (NCT02882321, Table 1) using IACS-010759,
a potent electron transport chain complex 1 inhibitor. This drug has shown cytotoxic efficacy by
inducing AMPK-dependent apoptosis in OXPHOS-reliant AML, likely owing to a combination of
energy depletion and reduced aspartate production that leads to impaired nucleotide biosynthesis [79].
Table 1. Modulators of metabolism and clinical trials on acute myeloid leukemia.
Drugs Drugs in Combination Clinical Trial Status
Targeting Oxidative
Phosphorylation (OXPHOS)
IACS-010759
NCT02882321
Phase I study to dose escalation and
dose expansion of the IACS-010759.
Active, recruiting [79]
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Table 1. Cont.
Drugs Drugs in Combination Clinical Trial Status
Targeting amino acid
metabolism
CB-839 Azacitidine
NCT02071927
Phase I/II study to evaluate the
dependence of AML and acute
promyelocytic leukemia on glutamine.
Completed, no results
posted [80,81]
Erwinase
(ASPARAGINASE)
NCT02283190
Phase I study to determine and analyze
the effects of Erwinaze/Asparaginase on
reducing serum glutamine levels.
Completed, no results
posted
GRASPA (L-asparaginase
encapsulated in red blood cells) Low-dose cytarabine
NCT01810705
Phase II study to evaluate the efficacy
and tolerability of GRASPA plus
low-dose cytarabine in treatment of
AML patients over 65 years old, unfit
for intensive chemotherapy.
Completed, no results
posted
PEG-BCT-100
(PEGylated recombinant human
arginase)
NCT02899286
Phase II, non-randomized, open-label
study to evaluate the efficacy of single
agent PEG-BCT-100 on arginine
depletion in adult patients with
relapsed/refractory AML.
Active, not recruiting
ADI-PEG 20
(arginine deiminase formulated
with polyethlene glycol)
NCT01910012
Phase II study to evaluate the response
rate of arginine depletion by arginine
deiminase.
Active, not recruiting
Targeting metabolic enzymes
and epigenetic modifiers
Enasidenib (AG-221)
NCT02577406
Phase III study comparing the efficacy
and safety of AG-221 versus
conventional care regimens in subjects
60 years or older with AML refractory
to or relapsed after second- or third-line
AML therapy and positive for IDH2
mutation.
Active, recruiting
Ivosidenib (AG-120) Azacitidine
NCT03173248
Phase III study to evaluate the efficacy
and safety of AG-120 plus azacitidine in
adult subjects with previously
untreated IDH1m AML who are
considered appropriate candidates for
non-intensive therapy.
Active, recruiting
IDH305
NCT02381886
Phase I study to estimate the maximum
tolerated dose/recommended dose for
expansion of IDH305 in patients with
advanced malignancies that harbor
IDH1 R132 mutations.
Active, not recruiting
BAY-1436032
NCT03127735
Phase II study to determine the
maximum tolerated and/or
recommended dose of BAY1436032, a
mIDH1 inhibitor in patients with
mIDH1-R132X advanced AML.
Completed, no results
posted
AG-881
NCT02492737
Phase I study to evaluate the safety,
pharmacokinetics, pharmacodynamics,
and clinical activity of AG-881 in
advanced hematologic malignancies
that harbor an IDH1 and/or IDH2
mutation.
Completed, no results
posted
FT-2102 Azacitidine or cytarabine
NCT02719574
Phase I/II study to evaluate the safety
efficacy, pharmacokinetics and
pharmacodynamics of FT-2102 as a
single agent or in combination with
azacitidine or cytarabine.
Active, recruiting
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Table 1. Cont.
Drugs Drugs in Combination Clinical Trial Status
Guadecitabine
NCT02920008
Phase III study of the efficacy and safety
of guadecitabine in adults with
previously treated AML.
Active, not recruiting
Oral azacitidine Best-supportive care
NCT01757535
Phase III study to compare efficacy and
safety of oral azacitidine plus
best-supportive care versus best
supportive care as maintenance therapy
in subjects with AML in complete
remission.
Active, not recruiting
Azacitidine Nivolumab
NCT02397720
Phase II study to determine the side
effects and the best dose of nivolumab
and azacitidine with or without
ipilimumab for treating patients with
AML that have not responded to
previous treatment or have returned
after a period of improvement or are
newly diagnosed.
Recruiting [82]
Signaling pathways and
autophagy inhibition
BKM120
NCT01396499
Phase I study to determine the highest
tolerable dose and the safety of
BKM120, a PI3K kinase inhibitor that
can be given to patients with relapsed
or refractory leukemia.
Completed, no results
posted
ONC201 Low-dose cytarabine
NCT02392572
Phase I/II study to find the highest
tolerable dose and safety of ONC201, an
inhibitor of the serine/threonine protein
kinase AKT and extracellular
signal-regulated kinase (ERK), alone or
in combination with low dose
cytarabine in patients with relapsed or
refractory AML, acute promyelocytic
leukemia, or myelodysplastic
syndromes.
Active, recruiting
Everolimus
MICE-regimen followed
by consolidation therapy
with idarubicin,
cytarabine, and
etoposide
NCT01154439
Phase I study to determine the
maximum-tolerated dose of everolimus,
a derivative of rapamycin that inhibits
mTOR, in combination with standard
remission-induction therapy
comprising mitoxantrone
hydrochloride, cytarabine, and
etoposide (MICE-regimen) followed by
consolidation therapy comprising
idarubicin, cytarabine, and etoposide in
older patients with newly diagnosed
AML.
Active, not recruiting
Sirolimus Azacitidine
NCT01869114
Phase II trial studies how well sirolimus
and azacitidine works in treating
patients with high-risk myelodysplastic
syndrome or recurrent AML.
Recruiting
Hydroxychloroquine (HCQ) Mitoxantrone andEtoposide
NCT02631252
Phase I study to find the safest and most
effective dose of hydroxychloroquine,
an autophagy inhibitor, when combined
with the usual medication for AML,
mitoxantrone, and etoposide.
Terminated, no results
posted
3.2. Targeting Amino Acid Metabolism
Glutamine dependence is a common metabolic strategy in many neoplasms, therefore constituting
a potential metabolic target to be explored [83]. Recently, it was reported that depleting glutamine
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in culture media or decreasing its catabolism trough GLS1 inhibition induced significant growth
suppression and cell death in AML cell lines [84]. Furthermore, the knockdown of the GLS1 and its
inhibition with CB-839 reduces OXPHOS, inhibits leukemic cell proliferation and induces apoptosis
without affecting normal CD34+ hematopoietic cells [84]. It was also shown that glutaminolysis
inhibition triggers mitochondria-dependent cell death and sensitizes AML cells to the BCL-2 inhibitor,
ABT-199 [80]. This combination is an example of synthetic lethality that has been explored in many
tumors by associating effective and less toxic drugs [24,85]. Another example is the combination of
glutaminase inhibitor CB-839 with the tyrosine kinase inhibitor (AC220-Quizartinib), which causes
major loss of viability through apoptotic cell death in FLT3-mutated AML cell lines and improves the
survival in a patient-derived xenograft AML mouse model [86]. A clinical trial that is now completed
used a combination of CB-839 with azacitidine, a DNA methyltransferase (DNMT) inhibitor, which has
in vitro and in vivo demethylating effects (NCT02071927, Table 1). Although no results were posted so
far, this same combination has been proven effective in up to 60% of patients with myelodysplastic
syndromes in a Phase III randomized controlled trial [87].
As mentioned above, asparagine is also a key player in the metabolism of malignant cells and
can be explored in therapeutic approaches. Since asparaginase is already approved for treating acute
lymphoid leukemia in children, it has been included in several clinical trials in AML patients integrating
strategies that contemplate the complex metabolism of asparagine and glutamine, or in combination
with low doses of cytarabine (NCT02283190 and NCT01810705, Table 1) [88].
Preclinical studies have demonstrated that AML blasts are dependent on arginine to proliferate
and survive since, at diagnosis, most leukemic cells have deficiencies in the arginine-recycling
pathway enzymes [89]. BCT-100, a pegylated recombinant arginase, causes a depletion of intra-
and extra-cellular arginine, resulting in halted proliferation of blasts and a reduction of engraftment
in vivo [89]. Depletion of arginine is, therefore, an important strategy of ongoing clinical trials
(NCT02899286 and NCT01910012, Table 1). Overall, there is an emerging interest in targeting amino
acid metabolism, given its crucial role in sustaining the growth and proliferation of malignant cells,
including AML ones.
3.3. Targeting Fatty Acid Metabolism
Both increased lipogenesis and FAO allow malignant cells to survive periods of metabolic
stress [30]. Some studies assessed the therapeutic potential of counteracting alterations of lipid
metabolism in AML [90]. For example, the drug ST-1326, an inhibitor of CPT1A crucial for the
acyl-CoA shuttling to mitochondria, slows the proliferation of leukemic cells and results in their
apoptosis, sensitizing these malignant cells to the cytotoxic effect of cytarabine [91]. Interestingly,
a small molecule with broad anti-tumor activity (SR9243) was described as simultaneously reducing
the intracellular concentration of glycolytic metabolites and preferentially suppressing lipogenesis in
malignant cells [92]. Conversely, FAO antagonizes the oligomerization of the pro-apoptotic components
BAX and BAK, thus compromising cell death and raising the threshold of response to pro-apoptotic
stimuli [93]. Furthermore, the FAO inhibitor Avocatin B was found to decrease NADPH levels and
cause reactive oxygen species (ROS)-dependent leukemic cell death in AML [94]. FAO is, therefore,
important for AML and its inhibition could become another potential target of cancer therapy. However,
given the complexity of lipid metabolism and its signaling network in cancer cells, it is still difficult to
select the best lipid dysregulation-targeting therapy.
3.4. Targeting Metabolic Enzymes and Epigenetic Modifiers
There are several clinical trials featuring drugs that inhibit mutated IDHs (Table 1) with promising
results and low toxicity profiles in both refractory/resistant leukemia patients and in untreated
patients [95]. Enasidenib (AG-221) is a covalent inhibitor of R140Q- and R172K-mutated IDH2 which
does not affect the activity of wild-type IDH2 [96]. In preclinical studies, enasidenib inhibited the
aberrant IDH2 protein, decreased total serum 2-HG levels in more than 90%, reduced abnormal histone
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hypermethylation, and restored myeloid differentiation [97]. Previous clinical trials with enasidenib
in relapsed or refractory AML patients provided positive results [98]. Currently, enasidenib is being
tested in a multicenter randomized phase III study (NCT02577406, Table 1). This drug is well tolerated,
but almost 12% of the patients experienced a differentiation syndrome similar to the one seen with
ATRA therapy in acute promyelocytic leukemia patients [99].
Ivosidenib (AG-120), IDH305, AG-881, BAY-1436032, and FT-2102 are some of the IDH1 inhibitors
under investigation (Table 1). Ivosidenib is being used in different ongoing clinical trials, and both the
patient response rates and differentiation syndrome (associated with the terminal differentiation of the
leukemic clone) are similar to enasidenib’s [100]. A small number of patients with complete remission
had clearance of the mutated clone and remained in the trial for over a year [95]. In a recent study
of ivosidenib monotherapy in advanced IDH1 mutated relapsed or refractory AML, similar results
were obtained with respect to the duration of remission, molecular remission, and therapeutic-related
adverse events [101]. In conclusion, these drugs are profiled as optimal agents for use in combination
strategies, since they act against specific targets and exhibit low extra-medullary toxicity.
Mutations in IDH1/2 and in the epigenetic modifier enzymes—DNMT3A and TET2—were
detected in more than 70% of AML patients [45]. All of these mutations are associated with epigenetic
aberrations in the pathogenesis of myeloblastic leukemia, so it is necessary to point out, albeit
briefly, the clinical experience acquired with drugs that act on DNA methylation. Decitabine and
5-azacitidine—hypomethylating agents—are standard drugs used in myelodysplastic neoplasms and
some AML subtypes with proven clinical efficacy and acceptable toxicity (NCT01757535, Table 1).
Several multicenter and randomized trials showed that they increase OS when compared to conventional
options, including low-dose-cytosine arabinoside and intensive chemotherapy [102,103]. It was also
found that decitabine was effective even in patients with high-risk karyotype and/or TP53 mutations,
constituting a possible therapeutic option in cases with poor prognoses [104]. In fact, these drugs
altered the treatment algorithm of elderly patients, since they have the capacity to prolong patient
survival, keeping the disease stable and/or improving cytopenia, even if remission is not achieved [105].
Guadecitabine is a new-generation hypomethylating agent with improved uptake of decitabine,
the active metabolite, into the DNA of rapidly dividing cancer cells [106]. Decitabine restores expression
of silenced tumor suppressor genes and tumor-associated antigens and may sensitize tumor cells to
other anticancer agents, including immunotherapeutic drugs. Guadecitabine is being used in clinical
trials (NCT02920008, Table 1) yielding good therapeutic responses, a pattern that overlapped with other
hypomethylating agents [107]. However, in hematologic malignancies, such agents have a double
effect on the immune system: they increase anti-tumor immune response and, conversely, dampen
the immune response by increasing the expression of immune-checkpoint molecules. Clinical trials
exploring the combination of hypomethylating agents (e.g., azacitidine) with immune-checkpoint
inhibitor drugs (e.g., nivolumab) are underway, with promising results (NCT02397720, Table 1) [82].
An important therapeutic strategy in AML is the combination of venetoclax (a BH3-mimetic that
blocks the anti-apoptotic BCL-2, frequently overexpressed in AML, reviewed in [108]) with low-doses
of cytarabine or decitabine or azacitidine in previously untreated patients older than 65 years [109].
Recently, it was shown that LSCs from patients undergoing treatment with venetoclax and azacitidine
displayed decreased levels of alpha-KG and increased levels of succinate, pointing at an alteration of
carbon flux in the TCA cycle, thus suggesting an efficient and targeted suppression of OXPHOS [110].
It was also found that IDH1- and IDH2-mutant primary human AML cells were more sensitive
than IDH1/2 wild-type cells to venetoclax, which was due to mitochondrial electron transport chain
alterations that lowered the threshold of apoptosis induced by this BCL-2 antagonist [111]. In view of
these promising assays, biomarkers are being studied that predict the efficacy of venetoclax in each
patient [112].
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3.5. Targeting Signaling Pathways and Autophagy
Due to the relevance of PI3K/AKT, mTOR, and AMPK on AML pathogenesis, these signaling
pathways present appealing therapeutic targets. In a murine model in which primary leukemic
cells were co-cultured with stroma, PP242, a mTOR inhibitor, simultaneously showed inhibitory
activity against mTORC1 and mTORC2 as well as an antagonism against the stromal-induced survival
signal, by suppressing expression of CXC chemokine receptor type 4 (CXCR4) [113]. This effect on
the medullary microenvironment should be emphasized, since this signaling affects the stemness of
leukemic precursors and contributes to chemoresistance of leukemic cells. Although the first mTOR
inhibitors (rapamycin and analogues) had a cytostatic effect and a low inhibitory growth effect, other
inhibitors subsequently demonstrated synergistic action with either standard chemotherapy, or with
other mTOR inhibitors [65,114]. In preclinical models, several dual mTORC1/2 inhibitors and dual
PI3K/mTOR inhibitors showed greater anti-leukemia activity [115,116]. The interactions between
mTORC1 and PI3K/AKT are complex, with mTORC1 exerting a negative control of PI3K/AKT that is
alleviated upon mTORC1 inhibition by sirolimus [117].
A potential mechanism for PI3K activation in AML might implicate increased VEGF levels [48].
Enhanced VEGF signaling has been proposed as a cause of reduced apoptosis susceptibility upon
AML treatment [118]. Recently, it was shown that blocking VEGF receptor 2 (VEGFR2) signaling
sensitized chemoAML (human AML cells from terminally ill mice treated with chemotherapy) to
chemotherapy by inducing a transcriptional program that promotes mitochondria biogenesis associated
with increased oxidative stress, further suggesting mitochondria function is a vulnerable target for
chemotherapy in AML [119].
AMPK pathway has also been implicated in hematological malignancies, mainly as a tumor
suppressor axis [63,120,121], by providing metabolic stress resistance to leukemia-initiating cells.
The anticancer properties of metformin were first associated with a complex mechanism of AMPK
activation, but recently different studies have demonstrated that antitumor effects of metformin— and,
globally biguanides—are AMPK-independent, reviewed in [59]. Notwithstanding this controversy
in the context of hematologic malignancies, metformin was reported to activate AMPK and inhibit
growth of AML cell lines and primary AML cells, while sparing normal hematopoiesis ex vivo [63].
However, additional studies in AML cell lines showed that metformin mediated effects on apoptosis,
and proliferation is preserved even in cells with siRNA-downregulated AMPK, thereby suggesting
AMPK-independent effects [122]. Among the direct activators of AMPK, GSK621 was reported to
selectively kill AML cell lines and primary cells without affecting normal hematopoietic progenitors [62].
Nevertheless, our previous results have shown that AMPK is constitutively activated in some AML
cell lines and that standard chemotherapy targets AMPK for degradation [12,56]. These somehow
contradictory results suggest that further studies should be performed to clarify the value of AMPK as
a therapeutic target.
Although several studies have demonstrated beneficial effects of drugs targeting signaling
pathways in preclinical models of AML, results of clinical trials are either modest, or disappointing
(reviewed in [115,123,124]). Table 1 illustrates some of the clinical trials targeting mTOR (NCT01154439
and NCT01869114) or PI3K/AKT (NCT01396499 and NCT02392572) signaling pathways.
Decreased mTOR activity as well as nutrient or growth factor deprivation increase autophagy,
therefore constituting an essential survival pathway [125]. Autophagy is critical for the maintenance of
HSCs, but plays context-dependent roles in leukemia initiation, progression, and drug resistance [126].
Autophagy is needed for the maintenance of murine HSCs and its impairment diverts normal
HSCs to a pre-leukemic state [67]. These findings are supported by evidence showing that
hematopoietic-specific deletions of ATG5, ATG7, or the ULK1-interacting partner Fip200 diminished
normal HSCs activities, promoted a pre-leukemic phenotype and, consequently, impaired survival of
these mice [66,69,127]. Other studies showed that ATG5 or ATG7 are required for the efficient initiation
of AML associated with MLL (mixed lineage leukemia)-AF9 fusion gene, while autophagy is no longer
required for the maintenance of established AML or LSCs functions in secondary xenotransplantation
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experiments [128–131]. In contrast, knockout of ATG5 or ATG7 in a murine MLL-ENL (eleven nineteen
leukemia) AML model decreased the number of functional LSCs, increased activation of mitochondria
and ROS levels in these cells, and extended survival of leukemic mice [132]. These aspects were
elegantly reviewed in [126].
Recently, it was also shown that autophagy suppression mediated by receptor tyrosine kinase
effectors-mTORC1 signaling stabilize mutant FLT3 in AML, while an increase in autophagy was
achieved through receptor tyrosine kinase inhibition and led to FLT3 depletion [71]. In contrast, a
different study showed that FLT3-ITD increases autophagy in AML cell lines and AML patient blasts,
and that inhibition of autophagy abolishes FLT3 inhibitor resistance [133]. Recent studies also revealed
inconsistent levels of basal autophagic flux in various leukemic cell lines [12,56,74] and purified CD34+
cells from AML patients [74]. Particularly high autophagic levels were found in poor risk AML, which
are frequently associated with TP53 mutations [74].
Altogether, these contradictory data suggest a highly complex, context-dependent role for
autophagy in leukemic transformation and LSCs properties in AML [126]. To further complicate
this scenario, autophagy is also established as one of the resistance mechanisms of leukemic cells to
chemotherapy [56,67]. However, although autophagy is generally considered a critical target in the
therapeutic approach to myeloblastic leukemia, it is documented that the effectiveness of this proteolytic
system will depend on the subtype of AML [12,134]. Clinical trials with hydroxychloroquine, an
inhibitor of autophagy, showed increased cytotoxicity of conventional chemotherapy in leukemic
cells (NCT02631252, Table 1) [135,136]. Although there are still diverging findings on this subject, it is
accepted that autophagy has a versatile role which depends, simultaneously, on both the progenitor
and driver engaged in leukemia’s transformation process, as well as the state of leukemic expansion.
4. Conclusions
AML is a very heterogeneous and complex group of diseases and, despite advances in therapeutic
strategies, there is still a high rate of resistance to the standard treatment. Accordingly, it is necessary
to find innovative ways of approaching and treating patients with AML. Age, performance status,
white blood cell count, secondary disease, cytogenetic risk, and the mutational state are incorporated
in the predictive models of resistance [137]. However, other variants such as the co-occurrence of
mutations, the minimal residual disease, and the emergence of sub-clones with a different sensitivity to
chemotherapy are also key players in the search for a more effective therapy [5,138]. In this context, it is
tempting to propose that the patient’s metabolic profile, as well as the metabolic phenotype of malignant
cells, may be considered prognostic factors in AML. The modulation of metabolic reprogramming
and the use of directed drugs open new promising possibilities in fighting AML. Nevertheless, results
supporting this hypothesis are mainly based on preclinical and in vitro studies—not on data from
clinical trials, which are still scarce. Another aspect to consider on metabolic targeting is that these
approaches will likely have a differential effect on normal hematopoiesis [139].
The results reviewed above show that energy metabolism is a fundamental process that should
be considered in AML therapy. Depending on the balance between glycolysis and OXPHOS, the
amino acid requirements of AML cells also change, and this could be useful for metabolic targeting.
Importantly, lipid metabolism is emerging with great therapeutic potential given the alterations found
in AML cells. Nevertheless, the knowledge of the complexities of lipid metabolism is still scarce,
and probably this is one of the reasons why no current clinical trials are found which feature drugs
targeting this axis of metabolic reprogramming. Summing up, more preclinical and clinical studies
have to be performed in order to establish the best metabolic target (or combination of targets) that
is better suited to affect LSCs sparing HSCs. Hopefully, the current preclinical and clinical ongoing
studies will shed light on the yet unknown aspects of metabolic reprogramming in AML.
In this review, we intended to provide an updated look at AML therapy; this new perspective
will, eventually, allow age constraints that current therapies still have to be overcome and, in addition,
facilitate the prediction of better results in refractory cases in the near future.
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